Abstract
Introduction: We compared the effectiveness of preemptive antiviral therapy for prevention of CMV disease using hyperimmune IVIG (Cytogam®; Medimmune) versus intravenous ganciclovir (Cytovene®; Roche Pharmaceuticals) in CMV-positive heart transplant recipients. In a prospective randomized trial, we analyzed data from 18 adult patients who underwent primary heart transplantation from 1997 to 2000.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
